Valuation : MetaVia Inc.

Market Cap 11.53M 9.92M 9.33M 8.53M 15.95M 1.09B 15.99M 110M 42.8M 558M 43.29M 42.35M 1.8B P/E 2026 *
-0.7x
P/E 2027 * -0.74x
Enterprise Value 11.53M 9.92M 9.33M 8.53M 15.95M 1.09B 15.99M 110M 42.8M 558M 43.29M 42.35M 1.8B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
71.39%
Yield 2026 *
-
Yield 2027 * -
1 day-4.89%
1 week+2.94%
Current month+1.74%
1 month+19.86%
3 months-28.57%
6 months+8.70%
Current year-79.22%
1 week 1.65
Extreme 1.65
1.93
1 month 1.42
Extreme 1.42
1.93
Current year 0.97
Extreme 0.9661
9.61
1 year 0.97
Extreme 0.9661
19.03
3 years 0.97
Extreme 0.9661
74.25
5 years 0.97
Extreme 0.9661
11,352.01
10 years 0.97
Extreme 0.9661
79,200.08
Manager TitleAgeSince
Chief Executive Officer 50 2023-08-10
Director of Finance/CFO 68 2023-10-26
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 55 2019-12-30
Director/Board Member 76 2019-12-30
Director/Board Member 50 2021-07-08
Date Insider Type Main position Quantity % Market Cap. Importance
1/23/26 Free

Chief Executive Officer

32,000 1.3913%
1/23/26 Free

Chief Financial Officer

28,000 1.2174%
8/12/25 Don

Chief Financial Officer

14,200 0.0725%
Change 5-day change 1-year change 3-year change Capi.($)
-4.89%+2.94%-76.84%-95.63% 11.53M
-1.79%-2.27%+50.90%+89.03% 67.98B
-2.06%-0.18%+41.53%+88.17% 64.94B
-0.31%+6.54%-11.39%+457.82% 27.58B
-3.00%-2.90%+39.40%+9.41% 25.74B
+0.86%+1.65%+0.25%-14.78% 26.06B
-1.46%+0.42%+24.07%-18.70% 20.09B
-2.96%-15.21%+210.71%+370.84% 17.16B
-1.49%-4.88%-0.41%+530.26% 14.92B
-0.20%+8.37%+57.87%+159.50% 14.62B
Average -1.73%+0.53%+33.61%+157.59% 27.91B
Weighted average by Cap. -1.52%+0.18%+42.29%+145.07%

Financials

2026 *2027 *
Net sales - -
Net income -19.62M -16.88M -15.88M -14.51M -27.14M -1.85B -27.21M -188M -72.82M -950M -73.66M -72.05M -3.06B -28.78M -24.76M -23.3M -21.28M -39.82M -2.72B -39.93M -275M -107M -1.39B -108M -106M -4.49B
Net Debt - -
Logo MetaVia Inc.
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
Employees
8
Date Price Change Volume
26-09-04 US$1.750 -4.89% 81,302
26-09-03 US$1.840 +1.10% 82,873
26-09-02 US$1.820 +5.81% 79,838
26-09-01 US$1.720 0.00% 51,461
26-08-31 US$1.720 +1.18% 23,772
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.750USD
Average target price
19.33USD
Spread / Average Target
+1,004.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MTVA Stock